4.2 Article

A Pituitary Society update to acromegaly management guidelines

期刊

PITUITARY
卷 24, 期 1, 页码 1-13

出版社

SPRINGER
DOI: 10.1007/s11102-020-01091-7

关键词

Pituitary adenoma; Acromegaly; Growth hormone; Insulin-like growth factor I; Somatostatin receptor ligand; Pegvisomant; Oral octreotide

资金

  1. Pituitary Society

向作者/读者索取更多资源

This article focuses on recent advances in the management of acromegaly, emphasizing how key developments affect treatment decisions and outcomes. It also explores the potential role of recently FDA-approved therapies and combination therapies in the treatment arsenal.
Guidelines and consensus statements ensure that physicians managing acromegaly patients have access to current information on evidence-based treatments to optimize outcomes. Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据